Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Rating of “Hold” from Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given a consensus recommendation of “Hold” by the twelve brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $6.64.

MRVI has been the subject of several analyst reports. Baird R W downgraded Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. UBS Group reduced their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a research report on Friday, March 21st. Bank of America lowered their price objective on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research note on Friday, March 21st. Finally, Morgan Stanley dropped their price target on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 25th.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $2.28 on Tuesday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The company has a market cap of $580.62 million, a price-to-earnings ratio of -1.39 and a beta of 0.25. Maravai LifeSciences has a 12 month low of $1.67 and a 12 month high of $10.03. The business’s 50 day simple moving average is $2.05 and its 200 day simple moving average is $3.59.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $46.85 million during the quarter, compared to analysts’ expectations of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The company’s revenue for the quarter was down 26.9% on a year-over-year basis. Sell-side analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current year.

Institutional Investors Weigh In On Maravai LifeSciences

Hedge funds have recently made changes to their positions in the business. Strs Ohio bought a new stake in shares of Maravai LifeSciences in the 1st quarter valued at about $429,000. McAdam LLC purchased a new position in Maravai LifeSciences during the 1st quarter valued at about $31,000. Jane Street Group LLC raised its position in Maravai LifeSciences by 1,463.1% during the 1st quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock valued at $841,000 after purchasing an additional 356,067 shares during the last quarter. Ascent Group LLC bought a new position in Maravai LifeSciences during the 1st quarter valued at approximately $41,000. Finally, Clearline Capital LP lifted its holdings in Maravai LifeSciences by 9.6% in the 1st quarter. Clearline Capital LP now owns 205,339 shares of the company’s stock worth $454,000 after buying an additional 18,000 shares during the period. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.